Download PDF CAMBRIDGE, Mass., Oct 26, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that financial results for the company’s third quarter ended September 30, 2011 will be released before the market opens on Wednesday, November 2, 2011. The AVEO management team will host a conference call discussing the company’s financial results
Download PDF CAMBRIDGE, Mass., Aug 31, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that the company’s management will present a company overview at upcoming investment conferences. David Johnston, chief financial officer, is scheduled to present at the William Blair 2011 Life Sciences Conference on Wednesday, September 7, 2011 at 2:00 p.m.
Download PDF CAMBRIDGE, Mass., Aug 02, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Canaccord Genuity 31st Annual Growth Conference on Tuesday, August 9, 2011 at 8:30 a.m. (EDT) in Boston. A live webcast of AVEO’s presentation can be
Download PDF CAMBRIDGE, Mass., Jul 28, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reviewed key second quarter accomplishments and reported consolidated financial results for the second quarter of 2011. “We are very pleased with the progress we have made against our corporate goals for 2011 in the first half of the year,
Download PDF CAMBRIDGE, Mass., Jul 21, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that financial results for the company’s second quarter ended June 30, 2011 will be released before the market opens on Thursday, July 28, 2011. The AVEO management team will host a conference call discussing the company’s financial results
Download PDF CAMBRIDGE, Mass., Jun 21, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has closed its previously announced underwritten public offering of common stock. The total number of shares sold was 6,352,119, comprised of 5,750,000 shares of common stock initially offered and an additional 602,119 shares of common stock
Download PDF CAMBRIDGE, Mass., Jun 15, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced the pricing of an underwritten public offering of 5,750,000 shares of its common stock at a price of $17.50 per share to the public. All of the shares are being sold by AVEO. The gross proceeds to AVEO
Download PDF CAMBRIDGE, Mass., Jun 14, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by AVEO. J.P. Morgan Securities LLC and Jefferies & Company, Inc. are acting
For media inquiries, please contact:
John F. Kouten, CEO
JFK Communications, Inc.
jfkouten@jfkhealth.com
Direct: 609-241-7352
The AVEO oncology management team comprises executives with years of oncology and pharmaceutical industry experience and expertise with a proven track record for success in bringing important new therapies to patients.